Key Findings
- Pathogenic fusions occur in approximately 3% of melanomas, with significant enrichment in BRAF/NRAS/NF1 triple-wild-type tumors and TERT promoter-mutant tumors.
- BRAF fusions are the most frequent fusion type in melanomas, followed by RAF1 and ALK fusions; specific fusions or fusion isoforms may define distinct subsets with potential clinical implications.
- This study represents the most comprehensive clinico-genomic characterization of pathogenic melanoma fusions to date, establishing a foundation for future studies.